L

Leap Therapeutics
D

LPTX

0.41380
USD
0.00
(0.34%)
مغلق
حجم التداول
0
الربح لكل سهم
-1
العائد الربحي
-
P/E
-0
حجم السوق
17,147,677
أصول ذات صلة
A
ARCT
-0.220
(-1.74%)
12.400 USD
BNTX
BNTX
1.870
(1.78%)
106.710 USD
C
CRNX
-0.427
(-1.33%)
31.783 USD
MRNA
MRNA
-0.670
(-2.45%)
26.680 USD
T
TBPH
0.100
(0.94%)
10.710 USD
V
VERU
-0.03590
(-5.55%)
0.61050 USD
المزيد
الأخبار المقالات

العنوان: Leap Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patientswith colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.